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Abstract Purpose: The epidermal growth factor receptor (EGFR) is amplified and overexpressed
in adult glioblastoma, with response to targeted inhibition dependent on the underlying
biology of the disease. EGFR has thus far been considered to play a less important role
in pediatric glioma, although extensive data are lacking. We have sought to clarify the
role of EGFR in pediatric high-grade glioma (HGG).
Experimental Design: We retrospectively studied a total of 90 archival pediatric HGG
specimens for EGFR protein overexpression, gene amplification, and mutation and as-
sessed the in vitro sensitivity of pediatric glioma cell line models to the small-molecule
EGFR inhibitor erlotinib.
Results: Amplification was detected in 11% of cases, with corresponding overexpres-
sion of the receptor. No kinase or extracellular domain mutations were observed; how-
ever, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two anaplastic
oligodendrogliomas and a gliosarcoma overexpressing EGFRvIII in the absence of gene
amplification and coexpressing platelet-derived growth factor receptor α. Pediatric glio-
blastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered
more sensitive to erlotinib despite expressing wild-type PTEN. Phosphorylated receptor
tyrosine kinase profiling showed a specific activation of platelet-derived growth factor
receptor α/β in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibi-
tion with erlotinib and imatinib leads to enhanced efficacy in this model.
Conclusions: These data identify an elevated frequency of EGFR gene amplification and
EGFRvIII mutation in pediatric HGG than previously recognized and show the likely
necessity of targeting multiple genetic alterations in the tumors of these children.
(Clin Cancer Res 2009;15(18):5753–61)
Amplification, overexpression, and/or mutation of the epider-
mal growth factor receptor (EGFR) represent a compelling set of
molecular genetic indicators for targeted therapy in adult glio-
blastoma. About 40% of glioblastomas show amplification of
the EGFR gene locus, and about half of these tumors express a
mutant receptor (EGFRvIII) that is constitutively active due to
an in-frame truncation within the extracellular ligand-binding
domain (1). In addition, novel missense mutations have been
reported in the extracellular domain of tumors and cell lines (2),
and recently, additional mutations have been described outside
of these regions (e.g., in the transmembrane domains), although
the significance of these is not yet clear (3).
EGFRvIII is caused by deletion of exons 2 to 7, resulting in a
protein that lacks a ligand-binding domain and is constitutively
activated and is further resistant to down-regulation due to a
low rate of receptor endocytosis (4). EGFRvIII has been shown
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to confer enhanced tumorigenicity both in human glioma cells
in vitro and in xenografts in immunodeprived mice (5, 6), and
in a xenograft model, tumorigenicity is directly proportional to
EGFRvIII receptor load (7). EGFRvIII has also been shown to
confer resistance to both radiotherapy and chemotherapy
(8, 9). Constitutive activation by EGFRvIII stimulates prolifera-
tion and inhibits apoptosis predominantly through stimulation
of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway but
also via the Ras/mitogen-activated protein kinase (MAPK) sig-
nal transduction pathway (10, 11). These data may explain the
observation that patients with EGFRvIII-expressing tumors have
a shorter interval to clinical relapse and poorer survival than
patients with EGFRvIII-negative tumors (12).
Erlotinib (Tarceva, OSI-774) is a selective inhibitor of the
EGFR tyrosine kinase and has shown activity in adult high-
grade glioma (HGG) patients (13). A differential therapeutic re-
sponse has been reported in these cases, with a variety of factors
reported to be predictive for treatment efficacy, including activat-
ingmutations of EGFR and a wild-type PTEN (14, 15). Published
preclinical data show equivocal results in adult glioblastoma
model systems engineered to overexpress the deletion mutant.
Erlotinib has been shown to inhibit EGFRvIII, blocking con-
stitutive EGFRvIII kinase activity and the growth of EGFRvIII-
transformed cells (15, 16). Furthermore, long-term exposure
to erlotinib decreased EGFRvIII expression in transformed cells
and selectively down-regulated the EGFRvIII-mediated induc-
tion of oncogenes that drive invasion in transformed glioblas-
toma cells (17). By contrast, other reports have shown that EGFR
amplification/mutation even in the presence of functional PTEN
did not render sensitivity to EGFR inhibitors (18, 19). This com-
bination of alterations may therefore be necessary but not suffi-
cient for conferring glioblastoma sensitivity to EGFR kinase
inhibition (20). Consequently, one could infer the existence
of additional determinants of glioblastoma sensitivity to EGFR
kinase inhibition yet to be identified. For instance, activating
mutations of PIK3CA, as recently shown in adult and pediatric
glioblastomas, could account for tumor insensitivity to EGFR
inhibition.
HGGs in children seem to be clinically and biologically dis-
tinct from their adult counterparts. Glioblastomas in adults are
classified as primary or secondary based on progression from
preexisting low-grade lesions and on distinct patterns of molec-
ular abnormalities (21). Although some molecular abnormali-
ties encountered in pediatric cases are reminiscent of secondary
adult glioblastoma [TP53 mutation (22) and platelet-derived
growth factor receptor α (PDGFRα) overexpression (23)], these
neoplasms rarely originate from preexisting low-grade lesions
(24). Unfortunately, our understanding of these differences is
restricted by the relative paucity of molecular data derived from
pediatric tumors.
EGFR has been considered to play a less important role in
pediatric HGG, although this issue is compounded by the
limited available data. The receptor seems to be frequently over-
expressed, usually in the absence of gene amplification, with
reports varying from 10% to 80% of pediatric nonbrain stem
HGGs (25–29). Interestingly, the primary site of the tumor may
affect the type of genetic changes involved, with data indicating
thatTP53mutation and EGFR overexpression are more frequent
in diffuse intrinsic pontine glioma than in supratentorial sites
in children (25).
We have sought to clarify the role of EGFR in pediatric HGG
and to assess the in vitro sensitivity of pediatric glioma cell line
models to erlotinib. These data identify a higher prevalence of
EGFR gene amplification and EGFRvIII mutation in pediatric
HGG than previously recognized.We further investigated the po-
tential of treatments targeting the receptor in deletion mutant-
positive cases.
Materials and Methods
Tumor samples. HGG samples from 90 patients were obtained after
approval by Local and Multicenter Ethical Review Committees. The col-
lection consisted of 53 glioblastoma multiforme, 16 anaplastic astrocy-
tomas, 3 anaplastic oligodendrogliomas, 3 brainstem gliomas, and 25
other WHO grade 3 or 4 lesions. All cases were archival formalin-fixed,
paraffin-embedded (FFPE) tissues. The presence of tumor tissue in these
samples and the tumor type was verified on a H&E-stained section in-
dependently by two neuropathologists (D.W.E. and S.A-S.).
Immunohistochemistry and chromogenic in situ hybridization. Immu-
nohistochemistry was done on representative 4- or 5-μm FFPE sections.
EGFR overexpression was assessed using the mouse monoclonal anti-
body 31G7 (Zymed) at a dilution of 1:50 using the Envision-HRP system
(K4006,Dako) as previously described (30). EGFRvIII was assessed using
a 1:100 dilution of the mouse monoclonal antibody G100 (Zymed) as a
primary and antigen retrieval bymicrowaving in 10mmol/L citrate buffer
(pH 6.0) for 3 × 5 min (31). PDGFRα was assessed using the polyclonal
rabbit primary antibody RB-1691 (LabVision) at 1:150 dilution with
15 min antigen retrieval in 10 mmol/L citrate buffer (pH 6.0; ref. 32).
Chromogenic in situ hybridization (CISH) was done using Spot-Light
amplification probes for EGFR (Zymed) according to the manufacturer's
protocol and as reported earlier (30). Cases were considered to be ampli-
fied for EGFR when >50% of the neoplastic cells harbored (a) more than
five signals per nuclei or (b) large gene copy clusters. Immunohistochem-
ical and CISH analyses were done with observers blinded to the results of
EGFR and sequencing data.
Mutation analysis. Genomic DNA was isolated from representative
10-μm-thick unstained tissue sections containing >85% tumor cells, as
determined from a serial H&E-stained section, using the QIAamp DNA
Mini kit (Qiagen) according to the manufacturer's instructions. Exons 2
to 8, coding for the extracellular domain of EGFR, and exons 18 to 21,
coding for the receptor tyrosine kinase (RTK) domain of EGFR, were
Translational Relevance
Dysregulation of epidermal growth factor receptor
(EGFR) is common in adult glioblastoma but has
been considered less so in the pediatric setting, al-
though unequivocal data have been lacking. This ar-
ticle details the largest and most comprehensive
study of EGFR gene alterations in high-grade glioma
of childhood yet undertaken. In addition to an elevated
frequency of gene amplification in comparison with
previous smaller series,we have identified for the first
time the presence of EGFRvIII deletions in pediatric
cases. By generating stably EGFRvIII-overexpressing
pediatric glioblastoma cell lines, we show that the
deletion is not sufficient to confer increased sensi-
tivity to the EGFR inhibitor erlotinib due to the specific
coactivation of platelet-derived growth factor recep-
tor α/β in these cells. Thus, we provide evidence for
a novel, pediatric-specific mechanism for erlotinib re-
sistance in glioblastoma.
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amplified by PCR (33). Products were purified using the QIAquick PCR
Purification kit and subjected to bidirectional sequencing using BigDye
Terminator Mix 3.1 (Applied Biosystems) according to the manufac-
turer's instructions. Capillary sequencing was done in duplicate on an
ABI 3100 genetic analyzer (Applied Biosystems), and sequences were
evaluated for the presence of mutations using Mutation Surveyor Soft-
ware (SoftGenetics LLC). A reverse transcription-PCR (RT-PCR) was de-
veloped for detection of the EGFRvIII mutation from FFPE sections.
RNA was extracted from representative 10-μm-thick unstained tissue
sections containing >85% tumor cells, as determined from a serial H&E-
stained section, using the Recover-All kit (Ambion). cDNAwas synthesized
from 200 ng RNA using SuperScript II reverse transcriptase (Invitro-
gen Ltd.). The deletion region was amplified with primers in exon 1
(5′-GGGCTCTGGAGGAAAAGAAA-3′) and exon 9 (5′-CCTCCATCTCA-
TAGCTGTCG-3′) amplifying a region of 91 bp when the deletion is pres-
ent and 892 bp in the wild-type. The presence of the EGFRvIII fragment
was confirmed in duplicate by direct sequencing.
Cell culture and generation of isogenic cell lines. Glioblastoma cell
lines U87MG and KNS42were obtained from the American Type Culture
Collection (LGC Promochem) and Japan Cancer Research Resources !s]
cell banks, respectively. SF188 was kindly provided by Dr. Daphne
Haas-Kogan (University of California at San Francisco, San Francisco,
CA), whereas UW479, Res259, and Res186 were kindly provided by
Dr. Michael Bobola (University of Washington, Seattle, WA). Cells were
grown as monolayers in DMEM/F12 Ham's medium + 10% FCS in 5%
CO2. EGFR constructs for isogenic cell lines were created by PCRs done
using Phusion DNA polymerase enzyme (Finnzymes) to minimize
the risk of error. Full-length wild-type EGFR was amplified from A431
cell line cDNA using the forward primer 5′-TCTTCGGCTAGCAAC-
GATGCGACCCTC-3′ and the reverse primer 5′-ATGCGGCCGCTCA-
TACTATCCTCCGTGGT-3′, which contained NheI and NotI enzyme
restriction sites, respectively. The EGFRvIII mutant was created using
splice overlapping extension PCR. Two PCRs were done to generate
two fragments with overlapping ends surrounding the deleted region
(exon 1: forward, 5′-TCTTCGGCTAGCAACGATGCGACCCTC-3′;
reverse, 5′-TGTCACCACATAATTACCTTTCTTTTCCTCCAGAGCC-3′;
exon 8: forward, 5′-GGAAAAGAAAGGTAATTATGTGGTGACAGAT-
CACGGC-3′; reverse, 5′-GCCGCGTATGATTTCTAGATTCTCAAAGGC-
3′). These fragments were then combined in a subsequent “fusion”
PCR inwhich the overlapping ends annealed, allowing 3′ overlap of each
strand to serve as a primer for the 3′ extension of the complementary
strand. The result was a fragment of 499 bp with EGFRvIII deletion and
NheI and XbaI restriction sites at the 3′ and 5′ ends. The remaining EGFR
cDNA sequence was amplified using forward primer 5′-GAATCTAGAAAT-
CATACGCGGCAGGACC-3′ and reverse primer 5′-ATGCGGCCGCTCA-
TACTATCCTCCGTGGT-3′, which contained XbaI and NotI enzyme
restriction sites. The vector F527 (34) was digested by NheI and NotI
and the PCR fragments by the enzyme corresponding to their restriction
sites. The cDNA fragment was then extracted from an agarose gel and pu-
rified using the QIAquick Gel Extraction kit (Qiagen). The ligation of in-
serts and vector F527 was done using T4 DNA ligase (Invitrogen).
Electrocompetent XL1 blue Escherichia coli (kindly provided by Betsy
Julienne, Institut de Cancérologie Gustave Roussy, Villejuif, France)
was transformed by electroporation in the presence of the ligation pro-
ducts, and selection was done by bacterial culture on ampicillin LB agar
Petri dishes. Colonies showing the correct orientation by restriction di-
gestion were further designated to sequencing. The DNA from plasmid
with the correct sequence was then efficiently isolated from E. coli using
Maxiprep using the PureLink HiPure Plasmid Filter Purification kit (In-
vitrogen). U87MG and SF188 were then transfected with either the F527
empty vector, or F527-EGFR wild-type or F527-EGFRvIII plasmids using
Lipofectamine (Invitrogen) according to the manufacturer's instructions.
Stable clones were obtained after 4 wk of antibiotic selection by 1 μg/mL
puromycin.
Western blot analysis. Cells at 80% confluence were trypsinized,
washed with PBS, and lysed for 1 h at 4°C in lysis buffer (Cell Signaling)
and a complete mini protease inhibitor cocktail (Roche Diagnostics).
Cells were then centrifuged at 11,000 rpm at 4°C for 15min, and protein
concentration was determined (bicinchoninic acid assay, Pierce). Total
protein extracts (30 μg/lane) were separated electrophoretically in 4%
to 20% SDS-polyacrylamide gel and transferred to nitrocellulose mem-
branes (Invitrogen). Immunodetection was done using antibodies
directed against EGFR, phosphorylated and total extracellular signal-
regulated kinase 1/2, phosphorylated/total Akt, and PTEN (all 1:1,000;
Cell Signaling) as well as glyceraldehyde-3-phosphate dehydrogenase
(1:2,000; Chemicon). Blots were revealed with peroxidase-conjugated
secondary anti-rabbit or anti-mouse antibodies (GE Healthcare) fol-
lowed by enhanced chemiluminescence solution (GE Healthcare).
Detection of phosphorylated RTKs. The levels of phosphorylated and
total wild-type EGFR were determined from 2.5 μg of protein lysate by
an electrochemiluminescent immunoassay (MesoScale Discovery) ac-
cording to the manufacturer's instructions. A phosphorylated RTK assay
(R&D Systems) was used to screen multiple RTKs. Cells were lysed in
radioimmunoprecipitation assay lysis buffer (Cell Signaling) and a com-
plete mini protease inhibitor cocktail (Roche Diagnostics), as described
for Western blot analysis. Phosphorylated PDGFRα/βwas measured in a
sandwich ELISA assay (Cell Signaling) according to the manufacturer's
instructions.
Growth inhibition studies. Erlotinib (Euroasian Chemicals PVT
Ltd.), imatinib (LC Laboratories), the dual PI3K and mammalian target
of rapamycin inhibitor PI-103 (provided by Piramed Ltd.), and the
MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitor
PD325901 (provided by Dundee University, Dundee, United Kingdom)
were obtained in powder form and diluted in either DMSO or water at
10 mmol/L stock solutions. Growth inhibition was determined using
the sulforhodamine B (SRB) assay as described previously (35). Briefly,
103 cells were seeded into 96-well microtiter plates and allowed to attach
for 36 h. Compounds at a range of concentrations were added in quadru-
plicate wells for 6 d (at least three doubling times) in a volume of 200 μL/
well. Cells were then fixed with ice-cold 10% trichloroacetic acid for
30 min, then washed with tap water, and dried. The plates were subse-
quently stained with 0.4% SRB in 1% acetic acid for 15 min, and excess
stain was washed off with 1% acetic acid. After the plates were dried, the
stain was solubilized with 10 mmol/L Tris base, and the absorbance was
determined at 570 nm. The IC50 was calculated as the drug concentration
that inhibits cell growth by 50% compared with control growth using
GraphPad Prism 4 program (GraphPad Software). All values are given
as mean ± SD of at least three independent experiments.
Statistical analysis. All statistical tests were done in R2.6.1.10 Corre-
lations between categorical values were done using the χ2 and Fisher's
exact tests. Correlations between continuous variables were done using
Student's t test or the Mann-Whitney U test. Cumulative survival prob-
abilities were calculated using the Kaplan-Meier method, with differ-
ences between survival rates analyzed with the log-rank test. All tests
were two tailed, with a confidence interval of 95%. P values of <0.05
were considered statistically significant.
Results
EGFR is amplified and overexpressed in pediatric HGGs. We
collected a series of 90 HGGs from patients under the age of
19 years (median, 11.3 years) for molecular analysis. All sam-
ples were archival FFPE pathology specimens, with variable
quantity and quality of material available as sections for immu-
nohistochemistry or DNA/RNA extraction. To evaluate gene
dosage and receptor expression of EGFR, we used CISH and im-
munohistochemistry on tissue sections.
We observed gene amplification in 8 of 74 (11%) evaluable
cases. These consisted of 6 glioblastomas (6 of 43, 14%) and 2
anaplastic astrocytomas (2 of 11, 18%). No amplifications were
10 http://www.r-project.org/
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seen in any other high-grade lesion. Polysomy of chromo-
some 7 was noted in an additional 14 of 74 (19%) cases and
included 10 cases of glioblastoma, 3 anaplastic astrocytoma,
and a gliosarcoma.
These amplifications were mostly present as dense clusters of
nuclear signals representing a high-level DNA copy number gain
in the vast majority of the tumor cells (Fig. 1, RMH2457); how-
ever, additional patterns were also observed. These included dis-
crete signals at a copy number of 9 to 10 per nucleus, observed
in a case of anaplastic astrocytoma (Fig. 1, RMH2480), or high-
density clusters, present only in scattered cells throughout the
tumor, in a glioblastoma (Fig. 1, RMH2449).
All cases of pediatric HGG harboring EGFR amplification
were found to express the protein at high levels (Fig. 1). There
was no association between EGFR amplification and clinical
outcome (P = 0.457, log-rank test for overall survival) or age at
diagnosis (P = 0.591, Mann-Whitney U test).
Pediatric HGGs harbor vIII deletions but no activating muta-
tions in the extracellular or kinase domains. We further screened
our pediatric HGG cases for mutations in the EGFR gene. Previ-
ously reported activating mutations in the kinase domain (in
non–small cell lung cancer and others) and the extracellular do-
main (adult glioblastoma) were screened by PCR amplification
of exonic sequences and direct sequencing. We observed no mu-
tations in 60 (kinase domain) and 66 (extracellular domain) pe-
diatric cases. Although the lack of kinase domain mutations is
consistent with data from adult glioblastoma, the absence of
extracellular domain mutations in our pediatric series is signifi-
cantly discordant with the published frequency of 18 of 132
(13.6%; ref. 2) in adult glioblastoma (P=0.0019, Fisher's exact test).
In addition, we developed a RT-PCR assay applicable to FFPE
samples to screen for the presence of the EGFRvIII deletion mu-
tation. A product of 91 bp spanning exons 1 and 8 was generated
from extractedmRNA in cases harboring deletion of exons 2 to 7,
which was verified by direct sequencing (Fig. 2). We detected six
cases of EGFRvIII in 35 assessable cases (17%). These included 1
of 20 (5%) glioblastoma, a single case of gliosarcoma, and an
increased frequency in anaplastic astrocytoma (2 of 6, 33%)
and anaplastic oligodendroglioma (2 of 3, 67%). Despite the
small numbers, these latter cases had a statistically significant
increased frequency compared with other pediatric HGG
(P = 0.036, Fisher's exact test). Interestingly, the glioblastoma
and anaplastic astrocytoma cases were EGFR amplified, whereas
the anaplastic oligodendroglioma and gliosarcomas were not.
A summary of mutation data is given in Table 1.
Pediatric glioma cell lines and response to erlotinib. In addi-
tion to the primary tumors, we also screened our panel of pedi-
atric glioma cell lines for EGFR mutations as described above.
None of five lines harbored any point mutations, deletions, or
amplifications nor significant levels of protein or mRNA expres-
sion of the receptor (data not shown). Treatment with the small-
molecule EGFR inhibitor erlotinib revealed a general lack of
sensitivity, with an IC50 of >50 μmol/L for most of the pediatric
cell lines. Themost sensitive cell line was the glioblastoma SF188
line (IC50 = 8.3 ± 0.7 μmol/L) derived from an 8-year-old male
patient, which is PTEN wild-type and harbors mutant TP53.11
Fig. 1. EGFR expression and amplification in pediatric HGG. H&E-stained sections, immunohistochemistry for wild-type EGFR, and EGFR CISH for three
representative cases of pediatric HGG. Amplifications were present either as discrete signals at a copy number of 9 to 10 per nucleus (RMH2480), in scattered
cells throughout the tumor (RMH2449), or in dense clusters in the vast majority of the tumor cells (RMH2457).
11 Bax DA*, Little SE*, Gaspar N, et al. Molecular and phenotypic characterisa-
tion of paediatric high grade glioma cell lines as models for preclinical drug
development PLoS ONE 4: e5209.
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Therefore, to study the effects of EGFR overexpression and
vIII deletion on pediatric glioma cells, we constructed isogenic
cell line models using the PTEN wild-type pediatric glioblas-
toma cell line SF188 as well as the PTEN-deleted adult glioblas-
toma line U87MG. We successfully transduced either EGFR
wild-type or vIII into both cell lines, resulting in stable protein
overexpression (Fig. 3A). Treatment of these cell line models
with erlotinib inhibited both PI3K and MAPK pathways and in-
duced a G1 arrest in all cells (Supplementary Fig. S1) but re-
vealed no statistically significant differences in efficacy
between EGFR-transduced (wild-type and vIII) and parental/
empty vector for both U87MG and SF188 (Fig. 3B). Isolated
clones showed a modest (2-fold) increase in sensitivity when
overexpressing the vIII deletion in both cell lines; however, this
was not generalizable. This was despite showing that vIII-trans-
duced cells harbored constitutive activation of the receptor, as
determined by an electrochemiluminescent immunoassay (de-
tecting transactivation of the endogenous EGFR rather than the
mutant) and also phosphorylated RTK array analysis (detecting
both wild-type and deletion mutant phosphorylation directly).
Mechanisms of resistance to erlotinib in SF188 cells. As EGFR
signals through both PI3K and MAPK, we sought to determine
whether the presence of either wild-type or mutant EGFR would
render glioblastoma cells more sensitive to agents inhibiting
these pathways. Regardless of PTEN status, there was no consis-
tent change in efficacy of EGFR-transduced U87MG or SF188
cells with the dual PI3K/mammalian target of rapamycin inhib-
itor PI-103 (Fig. 4A; refs. 36, 37) or the MEK inhibitor
PD325901 (Fig. 4B).
We next focused on the pediatric SF188 line to investigate the
possible biological basis for the lack of increased efficacy of
erlotinib in EGFR-overexpressing clones despite these cells har-
boring wild-type PTEN. Selecting the most erlotinib-sensitive
clones transduced by EGFR, we first showed that there was no
difference in response to small-molecule inhibition due to either
mutant or wild-type EGFR expression over a period of 72 hours
despite a modest diminution of downstream signaling in the
EGFR mutant SF188 cells (data not shown).
In U87MG cells, there is coactivation of EGFR and MET,
which allows for continued oncogenic RTK signaling in the
presence of small-molecule inhibition of EGFR (38, 39). To
look for similar association in our pediatric glioma cells, we as-
sayed the SF188 clones with phosphorylated RTK antibody ar-
rays (Fig. 5). There was only very low levels of constitutive
EGFR activation in the control cells, reflecting the data from
the electrochemiluminescent immunoassay (Fig. 3C and D),
and no additional RTK activation. There was an increase in
phosphorylated EGFR on transduction with the wild-type re-
ceptor and a further significant increase on constitutive activa-
tion by the EGFRvIII deletion mutant. In concert with this, we
observed a significant up-regulation of phosphorylated
PDGFRα and PDGFRβ as well as a modest increase in activated
MER, Tie-2, and Flt-3 (Fig. 5A). The increased levels of phos-
phorylated PDGFRAα/β were confirmed by a sandwich ELISA
assay in our SF188 model (Supplementary Fig. S2) and were not
seen in U87MG:EGFR wild-type or vIII mutant-overexpressing
cells (data not shown). Four of the six (50%) pediatric HGG sam-
ples positive for EGFRvIII also showed strong expression of
Table 1. Summary of EGFR mutations in pediatric HGGs
WHO grade Amplification (CISH) vIII deletion (RT-PCR) Extracellular domain Kinase domain
All pediatric HGG — 8/74 (11%) 6/35 (17%) 0/66 0/60
Glioblastoma multiforme IV 6/43 (14%) 1/20 (5%) 0/34 0/30
Brain stem glioma IV 0/3 0/1 0/3 0/2
Anaplastic astrocytoma III 2/11 (18%) 2/6 (33%) 0/12 0/12
Anaplastic oligodendroglioma III 0/4 2/3 (67%)* 0/4 0/4
Other pediatric HGG — 0/13 1/5 (Gliosarcoma) 0/13 0/12
*Significantly higher than that seen in other tumors (P = 0.036, Fisher's exact test).
Fig. 2. Detection of EGFRvIII deletions in pediatric HGG. A, lane 3, RT-PCR amplifying a product of 91 bp in EGFRvIII-positive cases. B, sequencing of the
RT-PCR product established the presence of sequence spanning exons 1 and 8 of the EGFR gene.
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PDGFRα protein by immunohistochemistry (Fig. 5B), a greater
frequency than the population as a whole (36%). Intriguingly,
these four cases included all those EGFRvIII-positive cases in
the absence of gene amplification (both anaplastic oligodendro-
gliomas and a gliosarcoma) as well as an anaplastic astrocytoma.
The number of positive cases was too small to assign a statistical
association (P = 0.14, Fisher's exact test) but shows the cosegre-
gation of these abnormalities in the clinical setting.
Finally, we tested whether inhibition of PDGFR would en-
hance the sensitivity of these cells to erlotinib treatment. We
measured cell viability of the SF188:EGFRvIII cells treated with
a fixed dose of 10 μmol/L erlotinib alone and in combination
with 10 μmol/L imatinib. Treatment with a combination of both
small molecules showed a significant decrease in cell viability
compared with either compound alone (P < 0.01, t test; Fig. 5C).
Discussion
Although the oncogenic significance of activated EGFR sig-
naling is well established in primary adult glioblastoma, in
the pediatric setting the picture is less clear. We have carried
out the largest molecular analysis to date of EGFR in the HGGs
of childhood and identified the presence of the EGFRvIII dele-
tion mutation in pediatric cases.
EGFRvIII was noted in WHO grade 4 glioblastoma and WHO
grade 3 anaplastic astrocytoma cases in association with gene
amplification and receptor overexpression. The few previous re-
ports on EGFR in pediatric gliomas suggested that amplification
was less common in pediatric glioblastomas than in adults, al-
though the frequency in these small series ranged from 0% to
25%, measured using a variety of different assays on differing
collections of tumor histologies (25–29). We observed an over-
all frequency of 11% amplification, with up to 14% in glioblas-
toma and 18% in anaplastic astrocytoma. Of particular interest
was the observation that in some cases the high-density clusters
of amplified probe signal were seen only in scattered cells
throughout the tumor. This may explain the underestimation
reported in earlier studies and highlights the benefit of using
a technique such as CISH to determine gene amplification, as
it allows histologic evaluation concurrent with the molecular
analysis.
Fig. 3. Glioblastoma cell lines stably overexpressing the EGFRvIII deletion mutant have constitutive activation but not increased sensitivity to erlotinib.
A, expression of EGFR and PTEN by Western blot in adult (U87MG) and pediatric (SF188) glioblastoma cell lines stably expressing EGFR wild-type (185 kDa)
and vIII deletion mutation (145 kDa). U87MG cells are PTEN deleted, and SF188 cells express the wild-type protein. B, sensitivity of the isogenic cell
lines to erlotinib, as determined by the SRB assay. There were no statistically significant differences in the IC50 values of any of the cell lines. C, constitutive
activation of the receptor, in EGFRvIII-overexpressing cell lines. Absolute counts for total and phosphorylated EGFR are plotted on a log10 scale. D,
percentage of phosphorylated EGFR to total protein, as determined by an electrochemiluminescent immunoassay, in the isogenic cell line models.
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We further observed EGFRvIII expression, in the absence of
gene amplification, in two of threeWHO grade 3 anaplastic oligo-
dendrogliomas and a single case of WHO grade 4 gliosarcoma.
Although there are no reports to our knowledge on the presence
of EGFRvIII in pediatric anaplastic oligodendrogliomas, the de-
letion has previously been identified in an adult case (40), and
more recently, we have observed 2 of 24 adult cases to harbor
the deletion (31). Both of these studies further reported that
Fig. 4. Pediatric glioblastoma cell lines transduced with wild-type or vIII deletion mutant EGFR were not rendered more sensitive to inhibitors of the PI3K or
MAPK pathways. Response of transduced U87MG and SF188 cells to inhibitors of PI3K/mammalian target of rapamycin (PI-103; A) and MEK (PD325901; B),
as determined by the SRB assay. There were no statistically significant differences in the IC50 values of any of the cell lines.
Fig. 5. Coactivation of PDGFRα/β in SF188 cells stably expressing EGFRvIII. A, phosphorylated RTK array analysis of isogenic SF188 cells shows low levels
of constitutive EGFR activation in the control cells, and no additional RTK activation, in contrast to a large increase on constitutive activation by the
EGFRvIII deletionmutant in association with a significant up-regulation of phosphorylated PDGFRα and PDGFRβ (also seen to a lesser extent with thewild-type
receptor) as well as MER, Tie-2, and Flt-3. B, immunohistochemistry for EGFRvIII and PDGFRα in a case of pediatric gliosarcoma (RMH2473) showing
coexpression of the receptors in the clinical setting. C, coinhibition of EGFR and PDGFR by erlotinib and imatinib showed a significant decrease in SF188:
EGFRvIII cell viability than either compound alone (P < 0.01, t test).
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the mutant receptor was amplified, and the significance of our
findings of EGFRvIII expression in the absence of amplification
is not clear; however, it may be significant that these anaplastic
oligodendroglioma cases also had strong PDGFRα expression, as
genomic alterations in EGFR and PDGFRA tend to be mutually
exclusive in pediatric glioblastomas (41). Intriguingly, in a
mouse model genetically engineered to express both EGFRvIII
and Ras under a GFAP promoter, GFAP-V(12)Ha-ras;GFAP-
EGFRvIII, but not GFAP-V(12)Ha-ras;GFAP-EGFR(wt) double
transgenicmice, had decreased survival and developed oligoden-
drogliomas and mixed oligoastrocytoma tumors, instead of the
fibrillary astrocytomas observed in GFAP-V(12)Ha-ras mice (6).
The role of EGFR, and specifically the vIII deletion mutant, re-
mains to be clarified in anaplastic oligodendroglioma, and asses-
sing the translational significance in children is hampered by a
lack of cell line models.
Activating mutations in the kinase domain of EGFR predict
for sensitivity to small molecular inhibitors in tumors such as
non–small cell lung cancer; however, these have not been re-
ported in adult glioblastomas, and their absence from our pedi-
atric series was not unexpected. By contrast, the identification of
oncogenic point mutations in the extracellular domains in adult
glioblastoma, and the resultant efficacy of receptor-targeting
strategies, led to the expectation that we may also observe these
base changes in childhood cases. The lack of suchmutations once
again serves to highlight the potential biological differences be-
tween gliomas arising at different ages.
Expression of the EGFRvIII mutant in association with wild-
type PTEN has been reported to predict for sensitivity to small-
molecule EGFR inhibitors, such as erlotinib, in the clinic (15),
although in some model systems constitutive EGFR activation
did not render the glioblastoma cells sensitive. We sought to
clarify the situation in the childhood disease by screening a se-
ries of well-characterised11 glioma cell lines derived from pedi-
atric patients for in vitro sensitivity to erlotinib. These lines,
consisting of both PTEN null and wild-type, all expressed
EGFR at only low levels and were relatively insensitive to
small-molecule inhibition by erlotinib. Transduction of the
PTEN-expressing pediatric glioblastoma cell line SF188 with
EGFRvIII did not greatly enhance the effects of erlotinib on cell
viability nor downstream signaling.
EGFRvIII and the wild-type receptor have recently been
shown to differentially activate downstream pathways, suggest-
ing that therapeutic approaches toward tumors expressing these
two distinct receptors should be fundamentally different (38).
The expectation that targeting the MAPK pathway in wild-type
EGFR, and the PI3K pathway in EGFRvIII-expressing cells, was
not borne out by our data with engineered SF188 or U87MG
cells, although in part this may be explained by the significant
transactivation of the wild-type receptor in cells transduced with
the mutant.
Previous reports have shown that coexpression of EGFRvIII
and PTEN in U87MG cells rendered them highly susceptible
to growth arrest by erlotinib compared with controls and
U87 cells transfected with EGFR wild-type and EGFRvIII alone
(15). In common with a recent study using a panel of serially
propagated glioblastoma xenografts (20), it seems from our
experiments with pediatric SF188 cells that the combination
of PTEN expression with EGFRvIII mutation may be in-
sufficient to confer obligate sensitivity to the small-molecule
inhibitor.
The above data strongly suggest the presence of additional
determinants of sensitivity to EGFR inhibitors in SF188 cells
and possibly to pediatric HGGs in the clinic. The recent dis-
covery of activating mutations in PI3K family member genes,
such as PIK3CA and PIK3R1, in malignant glioma reiterates
the importance of multiple mechanisms to increase signaling
through this pathway (3, 42). SF188 harbors amplification at
chromosome 12q14 of several genes, including CDK4 and
CENTG1, also known as the PI3K enhancer PIKE-A (43), a
ubiquitously expressed GTPase, which binds to and enhances
Akt kinase activity in a guanine nucleotide–dependent man-
ner (44). Additional genomic aberrations in SF188 include
amplification of MYC at 8q24,11 which can be stabilized by
PI3K (45) and provides an additional attenuation of this path-
way in SF188 cells. Both amplification events have been reported
in pediatric glioblastoma patient samples (43, 46).
Coactivation of RTKs, and the concept of “kinase switch-
ing,” is an emerging concept that may additionally explain
the lack of efficacy of agents targeting activated RTKs, such
as EGFR. In adult glioblastoma, EGFR and MET seem
frequently to be coactivated, with in vitro data supporting
cotargeting both receptors (39). Furthermore, in adult glio-
blastoma models, the MET receptor seems strongly phos‐
phorylated as a function of EGFRvIII levels. This has been
hypothesized to be a result of an intermediary signaling com-
ponent such as Src, as has been postulated for human blad-
der carcinoma (38). In the pediatric SF188 cells, we observed
a significant activation of the closely related PDGFRs
PDGFRα and PDGFRβ on transduction with EGFRvIII (and
to a lesser extent with the wild-type receptor). We have pre-
viously reported high levels of Src family kinase expression in
pediatric glioma cell lines, and SF188 in particular,11 and the
role of these key regulators of signal transduction in the
transactivation and/or switching between constitutively acti-
vated EGFRvIII and PDGFRα/β warrants further investigation.
The identification of EGFRvIII deletions in pediatric HGGs
and the possible resistance mechanisms to EGFR inhibitors
conferred by known oncogenic amplifications have signifi-
cant translational potential. In particular, PDGFRs are over-
expressed at high frequency in pediatric glioblastomas, and
specifically with three of six EGFRvIII-positive cases in this
study, and this may be due to a differential, amplification-in-
dependent mechanism of action in anaplastic oligodendro-
gliomas. Coupled with evidence of enhanced efficacy from
our in vitro model systems, these data provide a strong ratio-
nale for cotargeting with small-molecule inhibitors of both
RTKs, potentially overcoming resistance to single agents in
appropriate patient cohorts (47).
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